Public prefers limited informed consent process for biobanks

June 29, 2011 in Genetics

Biobanks are repositories for tissue samples, usually in the form of blood or saliva or leftover tissue from surgical procedures. These samples are collected and used for future research, including genetic research. They may be linked to personal health information regarding the sample donor. People who are eligible to donate these samples and researchers who want to use them face important questions with respect to whether and how informed consent should be obtained for sample and health information collection and use.

A team of University of Iowa researchers led by Christian Simon, Ph.D., associate professor of and humanities in the Department of at the UI Roy J. and Lucille A. Carver College of Medicine, conducted a study to determine people's preferences with respect to for biobanking. The study, "Active choice but not too active: Public perspectives on biobank consent models," was published ahead of print in last month's online edition of the journal, Genetics in Medicine. The study involved 751 telephone surveys and seven focus groups with English-speaking members of the public who were randomly sampled from counties across Iowa. Over half the study participants were female.

Most study participants had not heard of a "biobank" before, but when it was explained to them what biobanks were and that they could help advance research on genetic and nongenetic aspects of disease, most study participants were enthusiastic.

The majority (95 percent) of survey participants rejected the idea of deriving and banking samples without first informing and asking patients for their permission—obtaining their informed consent.

"This speaks to the premium many people place on being informed and having a choice about participating in research," Simon said.

Participants were also asked whether they would prefer to opt in or out of biobank participation.

"This distinction is important because opt-in consent typically involves more detail, more time and a more active decision on research participation when compared to an opt-out process," Simon explained.

Sixty-seven percent of those surveyed and 63 percent of those who participated in the focus groups said they would prefer an opt-in consent process.

"Nonetheless," Simon said, "a substantial minority -- 18 percent in the surveys and 25 percent in the focus groups -- said they would prefer an opt-out process, primarily because they felt it provided at least some level of choice, involved less time for potential donors and fewer resources for the biobank, and would help with accrual and therefore also medical research and progress."

were then asked to consider whether they would prefer a broad description of how their samples and might be used in future research, whether they wanted to control what research their samples and health information are used in via "menu-type" consent forms, or whether they wanted to be contacted for their permission every time their samples and health information became eligible for research.

"Broad consent was preferred by more people when compared to either the menu or study-specific types of consent," Simon said. "However, if you were to lump together the people who said they preferred the menu and study-specific types of consent on the grounds that both these approaches promote more control over sample use than broad consent, the margin is not so impressive."

Forty-one percent of people surveyed – and 54 percent of those in focus groups – were in favor of the broad approach to providing consent.

Simon noted that some experts have suggested that more than one consent approach should be offered to people to allow for a diversity of consent preferences.

"Of course, there may be significant cost and logistic implications to creating such multiple options," Simon said.

He said the study findings will provide a starting point for discussions about consenting patients to a new comprehensive tissue biobank at UI Hospitals and Clinics, which will house thousands of for future research purposes. The tissue will be accessed for DNA as well as RNA, Simon said.

"Biobanks are going to be – already are – dependent on public support and participation," Simon said. "Putting into place an informed consent process that meets formal requirements and standards and that works for people by taking their values and preferences into account is one way that we can reach out and build public support and trust for biobanks."

Provided by University of Iowa Health Care

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Genetics created 22 hours ago | popularity 3 / 5 (2) | comments 0 | with audio podcast

Patenting the human genome

Can human genes be patented? That was the question posed by Alan J. Snyder, vice president and associate provost for research and graduate studies at Lehigh, and Lee Kaplan, scientific director of cellular and molecular genetics ...

Genetics created May 24, 2013 | popularity 4 / 5 (1) | comments 0

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Genetics created May 22, 2013 | popularity 4.5 / 5 (4) | comments 0 | with audio podcast

Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors

University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...

Genetics created May 20, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Researchers identify new circadian clock component

Northwestern University scientists have shown a gene involved in neurodegenerative disease also plays a critical role in the proper function of the circadian clock.

Genetics created May 16, 2013 | popularity 3 / 5 (1) | comments 1 | with audio podcast


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...

Driving and hands-free talking lead to spike in errors, study shows

Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.

Comorbidities common with alopecia areata

(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.